Francis will lead Actuate’s continued global expansion, strengthen its channel partnerships, and advance its position as a fast-growing monitored video AI provider. Actuate, a provider of vision ...

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment ...

It’s a huge challenge, but if we all act together, there is hope. We’re pushing the UK for the strongest ambition and measures to help tackle the climate emergency. We’re doing this by influencing ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Read Less In this article, we consider the case for investing in UK funds. We’ve also asked Rob Morgan, investment analyst at wealth managers, Charles Stanley, to identify five UK funds suitable ...

Since the end of World War Two, immigration has transformed the UK. After the war, fewer than one in 25 of the population had been born outside the country; today that figure is closer to one in ...

The UK has pledged to reach "net zero" - where no additional planet-warming greenhouse gases are added to the atmosphere - by 2050. To achieve this, much more of our energy needs to come from ...

NEW YORK—Actuate, a global provider of vision-based AI monitoring solutions, has announced the appointment of Ken Francis as CEO. With over two decades of experience at the helm of industry-leading ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product ...

This page features the latest news about the Actuate Therapeutics stock. Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development Companies will discuss how Lantern's AI ...